Latest from UCSF Helen Diller Family Comprehensive Cancer Center

Hope S. Rugo, MD, discusses the updated data from the phase III SOPHIA trial for patients with HER2-positive metastatic breast cancer who had received prior anti-HER2 therapies, presented at the 2019 San Antonio Breast Cancer Symposium.
Adil Daud, MD, discusses the combination of dabrafenib and trametinib versus immunotherapy in patients with BRAF V600-mutant metastatic melanoma.
Adil Daud, MD, discusses the role of dabrafenib plus trametinib in patients with advanced melanoma and highlighted other combinations under investigation.
Adil Daud, MD, clinical professor, Department of Medicine (Hematology/Oncology) and director, Melanoma Clinical Research, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses research evaluating interferon gamma as a potential biomarker of response in melanoma.
The use of immunotherapy in cancer was solidified by the ample activity seen in patients with melanoma.
Adil Daud, MD, clinical professor, Department of Medicine, director, Melanoma Clinical Research, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the immunogenicity of melanoma.
Margaret A. Tempero, MD, discusses the impact of FOLFIRINOX in the treatment of patients with metastatic pancreatic cancer and sheds light on the importance of molecular profiling in the space.
Matthew A. Gubens, MD, MS, discusses an update to the NCCN Guidelines regarding patients with PD-L1 non–small cell lung cancer.
Publication Bottom Border
Border Publication
x